Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)

Q: What does this research mean for the field?

Furmonertinib-based triplet therapy, combining an antiangiogenic agent and chemotherapy, significantly improves overall survival compared to mono or dual therapy in patients with EGFR-mutant non-small-cell lung cancer and leptomeningeal metastases. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

H. Chen; H. Xu; Z. Yin; X. J. Li; G. Lin; T. Xin; H. Yang; Q. Zhao; W. Cheng; L. Zhang; H. Li; W. Xu; H. Zheng; C. Fan; F. Wang; L. Guo; Y. Wu; Y. Wu; S. Yang; X. Tang; C. Zhu; s. Fang; Q. Wang

doi:10.1016/j.esmoop.2026.107743

June 1, 2026ESMO OpenOpen Access

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy of furmonertinib-based therapy in patients with EGFR-mutant NSCLC and leptomeningeal metastases.
Large-scale, multicenter, retrospective study involving 618 patients treated with furmonertinib-based regimens.
Endpoints included overall survival, time to treatment failure, clinical response rate, and treatment-related adverse events.
Comparison of triplet therapy with mono and dual regimens.
Median overall survival was 14.19 months; triplet therapy showed longer OS of 17.91 months (P < 0.001).
Patients with poor performance status had an OS of 17.31 months on triplet therapy (P = 0.003).
Treatment-related adverse events occurred in 59.2%; grade 3-4 events were reported in 7.9%.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Retrospective study finds furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases, suggesting better therapeutic strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a265becad53cfb9357c53eb https://doi.org/10.1016/j.esmoop.2026.107743

View Full Paper

Ask AI

Bookmark

Share

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading